The future of primary care will be collaborative by design. Clinicians will continue to be the first call and the trusted guide, but they will be supported by scientific partners who shorten the distance between breakthrough and bedside. The post The Primary Care Clinician of the Future Won’t Practice Alone: The Power of Scientific Partnerships…
Hemab Therapeutics and Seaport Therapeutics are the newest biotech companies to join the public markets, each with an upsized IPO. According to IPO research firm Renaissance Capital, April was the biggest month for biotech IPO proceeds in more than five years. The post Four Biotech IPOs Raise $1.5B in April, the Biggest Month in Five…
By MICHAEL MILLENSON Open enrollment season for Medicare, which began Oct. 15 and ends Dec. 7, triggers a deluge of information about various options. Since I’m a health care consultant and researcher as well as a Medicare beneficiary, I’ve looked critically at what we’re told and what we’re not. Unfortunately, information crucial both for the…
Amvuttra, an Alnylam drug approved to treat nerve pain from transthyretin amyloidosis, is now FDA-approved for treating cardiomyopathy caused by this disease. The approval brings Amvuttra to a much bigger market, but it must compete with a blockbuster Pfizer drug already established as the standard of care. The post Alnylam Drug Approval Brings Cardiomyopathy Competition…
Prior to the first fall presidential debate, a growing share of voters see the election as a referendum on abortion access, and Vice President Harris holds a strong advantage over former President Trump on the issue. The economy and inflation remain voters’ top issue, and many want to hear the candidates address health care costs.
Colon cancer has long been considered a disease that comes with old age. However, the trend line of disease has been moving in the wrong direction for years, in a population we long assumed wasn’t at risk. And while researchers continue to investigate the why, there’s a parallel conversation we aren’t having nearly enough. One…
This analysis presents key facts about hospitals with more than 40 charts related to national spending on hospital care, characteristics of the hospital industry, rural hospitals, use of hospital care, out-of-pocket spending and medical debt, hospital prices, hospital finances, and charity care.
This Monitor highlights April KFF Tracking Poll findings on perceptions about measles and explores the unsubstantiated promotion of budesonide and clarithromycin as treatments. It also covers misrepresentations of syringe programs and how prompting strategies can boost the accuracy of AI chatbots on health questions.
One CIO discusses the process of adopting a new EHR system at their organization
The survey provides an in-depth look at trends in employer-sponsored coverage in California, including premiums, cost sharing, offer rates, and employer strategies to manage costs and access to care, including comparisons to the nation overall.